Jung-jin Seo, Chairman of Celltrion Group, a leading Korean biopharmaceutical company, joins The Korea Society’s President, Tom Byrne for a conversation on the race to develop antibody treatments for the COVID-19 virus. Together, they will discuss the role of the Korean biopharmaceutical industry and Celltrion’s active involvement in combating COVID-19. Join us to learn about how K-bio’s work fits into global efforts to combat the pandemic.

COVID LESSONS FROM SOUTH KOREA:
A Conversation with Celltrion Group Chairman Mr. Jung-jin Seo
& Korea Society President Tom Byrne

Premieres: Friday, February 19, 2021 | 7 PM EST

The Korea Society
350 Madison Avenue, 24th Floor
New York, NY 10017

ABOUT THE SPEAKER

Jung-jin Seo Chairman of Celltrion Group Jung-jin Seo is the founder and Chairman of Celltrion Group, a leading Korean biopharmaceutical company. A native of Cheongju, South Korea, Mr. Seo established Nexol Biotech, which later became Celltrion, after building his career at Samsung Electro-Mechanics, Korea Productivity Center, and Daewoo Motors. Mr. Seo graduated from Konkuk University majoring in industrial engineering. Founded in 2002, Celltrion specializes in the research and development of various biologics, especially monoclonal antibody therapies. Celltrion received approval from EMA and FDA for the world’s first mAb biosimilar, Remsima® (INFLECTRA®). With extensive experience in developing monoclonal antibody biosimilars, Celltrion is actively enhancing its business in biobetters, innovative drugs, and small molecule drugs. The firm is also developing Covid-19 antiviral antibody treatment to fulfill its responsibility as a leading biopharmaceutical company.